4D Molecular Therapeutics Inc
NASDAQ:FDMT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
|
SA |
|
Piccadily Sugar and Allied Industries Ltd
BSE:507498
|
IN |
|
Branicks Group AG
XETRA:BRNK
|
DE |
|
E
|
Emperor Metals Inc
CNSX:AUOZ
|
CA |
|
A
|
Avadh Sugar & Energy Ltd
NSE:AVADHSUGAR
|
IN |
|
Ootoya Holdings Co Ltd
TSE:2705
|
JP |
|
Siemens Energy AG
XETRA:ENR
|
DE |
|
Chemcon Speciality Chemicals Ltd
NSE:CHEMCON
|
IN |
4D Molecular Therapeutics Inc
Accounts Payable
4D Molecular Therapeutics Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
Accounts Payable
$11.2m
|
CAGR 3-Years
50%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$34.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
23%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$715m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$20.9B
|
CAGR 3-Years
137%
|
CAGR 5-Years
71%
|
CAGR 10-Years
36%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$3.9B
|
CAGR 3-Years
134%
|
CAGR 5-Years
91%
|
CAGR 10-Years
48%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$6.8B
|
CAGR 3-Years
126%
|
CAGR 5-Years
70%
|
CAGR 10-Years
47%
|
|
4D Molecular Therapeutics Inc
Glance View
4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. The company is headquartered in Emeryville, California and currently employs 124 full-time employees. The company went IPO on 2020-12-11. The firm is focused on creating and developing targeted and evolved adeno-associated viruses (AAV) vectors. The Company’s product candidates are focused various areas, including ophthalmology, cardiology, and pulmonology. The firm's product candidates include 4D-125, 4D-150, 4D-110, 4D-310, and 4D-710. 4D-125 for the treatment of patients with X-Linked Retinitis Pigmentosa (XLRP) with retinitis pigmentosa GTPase regulator (RPGR) gene. 4D-150 is developed for the treatment of wet age-related macular degeneration (wet-AMD). 4D-110 is developed for the treatment of choroideremia. 4D-310 is developed for the systemic treatment of Fabry disease. The firm is developing 4D-710 for the treatment of a broad range of patients with cystic fibrosis independent of their cystic fibrosis transmembrane conductance regulator (CFTR).
See Also
What is 4D Molecular Therapeutics Inc's Accounts Payable?
Accounts Payable
11.2m
USD
Based on the financial report for Dec 31, 2025, 4D Molecular Therapeutics Inc's Accounts Payable amounts to 11.2m USD.
What is 4D Molecular Therapeutics Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
44%
Over the last year, the Accounts Payable growth was 154%. The average annual Accounts Payable growth rates for 4D Molecular Therapeutics Inc have been 50% over the past three years , 44% over the past five years .
